Melanoma, Sarcoma and GU Tumors Unit, Catalan Institute of Oncology Hospitalet, Barcelona, Spain
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.
Benjamin Speich, Florian Naudet, Arnav Agarwal, Francesco Sclafani, Juan Martin-Liberal +9 more
Driven by 2 papers — median percentile 78. Top paper: “Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016”.
Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal, Tiago V. Pereira +12 more
Benjamin Speich, Florian Naudet, Arnav Agarwal, Francesco Sclafani, Juan Martin-Liberal +9 more